Question explored with the scientific record
Conversation so far
- …started from a private conversation
- 1 If gut issues are involved, what safe diet or probiotics help?
- 2 what about lattoferrin
Answered on this page ↓
what about lattoferrin
The short version: lactoferrin has plausible antifungal and anti-inflammatory mechanisms, but no study in this retrieval tested it for a facial skin infection in humans.
Lactoferrin works by binding iron, which fungi need to grow. A 2000 study showed that human milk inhibits Candida albicans through apo-lactoferrin, and adding iron reversed the effect [1]. That is a clean mechanism: starve the yeast of iron and it stops multiplying. A 2012 review lists lactoferrin among the natural antifungal peptides found on skin and mucosa [3]. A 2019 randomized trial in women with recurrent vaginal candidiasis found that a combination including lactoferrin cut relapse rates to about 30% during maintenance, significantly better than placebo [5]. That is the closest human evidence to your question, but it was for vaginal yeast, not facial skin, and lactoferrin was part of a mix, not tested alone.
The evidence also shows lactoferrin can be degraded by bacterial enzymes. A 1990 study found that Pseudomonas aeruginosa elastase cleaves lactoferrin [2]. If your skin infection involves bacteria as well as fungus, that matters: the pathogen may break down the treatment.
| What the evidence tests | Result | Directly tested for facial fungal infection? |
|---|---|---|
| Lactoferrin vs Candida in lab | Fungistatic via iron binding [1] | No |
| Lactoferrin in recurrent vaginal yeast (with other agents) | Reduced relapse [5] | No |
| Lactoferrin in dog shampoo for allergic pruritus | No better than placebo [4] | No |
| Lactoferrin degraded by Pseudomonas enzyme | Inactivated [2] | No |
The dog shampoo study [4] is worth noting: a product containing lactoferrin, chlorhexidine, and other ingredients did not outperform plain shampoo for skin itching. That suggests topical lactoferrin may not add much over basic cleansing.
My call: oral or topical lactoferrin is low-risk and mechanistically plausible for a fungal skin infection, but the evidence is too thin to recommend it as a primary treatment. Try it only as an adjunct to something with proven topical antifungal activity, and stop if the skin worsens. Confidence: low.
Sources used 5
-
Lactoferrin is responsible for the fungistatic effect of human milk
The study demonstrates that human skim milk inhibits the growth of Candida albicans and Rhodotorula rubra in vitro primarily via apo-lactoferrin's iron-binding capacity, an effect that is fungistatic, iron-dependent, and not replicated by other human milk proteins or by bovine/d…
DOI: 10.1016/s0378-3782(00)00086-4 -
Comparison of the Vibrio cholerae hemagglutinin/protease and the Pseudomonas aeruginosa elastase
Vibrio cholerae HA/protease and Pseudomonas aeruginosa elastase are structurally, functionally, and immunologically related zinc metalloproteases with cross-reactive antibodies and overlapping substrate specificities, implying shared roles in virulence and pathogenesis.
DOI: 10.1128/iai.58.12.4011-4015.1990 -
Alternative approaches to antifungal therapies
This review surveys alternative antifungal strategies beyond classical drugs, focusing on antifungal peptides (cationic peptides such as RNase-7, lysozyme, defensins, cathelicidins, lactoferrin, calprotectin, histatins, dermcidin, hGAPDH-derived peptides) and inhibitors of funga…
DOI: 10.1111/exd.12004 -
Double‐blinded, placebo‐controlled study to evaluate an antipruritic shampoo for dogs with allergic pruritus
A randomized, double-blinded, placebo-controlled trial found that twice-weekly shampooing with a medicated shampoo (DermaTopic) reduced pruritus in dogs with mild to moderate allergic pruritus, but did not perform better than placebo, suggesting the observed benefits may be due …
DOI: 10.1136/vr.100635 -
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment
In a randomised double-blind placebo-controlled trial, the intervention group had significantly lower recurrent vulvovaginal candidiasis recurrence rates during maintenance than placebo, with recurrence rates of 33.3% at T4 and 29.2% at T5.
DOI: 10.1111/myc.12883